Submitted Projects:

The company product portfolio is centered around innovative adhesive composites that can out-compete today’s Standard-of-Care metal implants for fracture fixations. Three product prototypes have already been preclinically validated by surgeons and BMB is now on open for investment that will allow the company to conduct First-in-Man study, CE marking and commercialization. Below is a summary of the USPs that accompanies the products:

– Developed due to the demand from surgeons
– Simple chemistry and scalable compositions
– Viable and personalized surgical method
– Fixation of complex fractures with increased freedom
– Topical, proper and maintained fixation without the need of metal plates. Loadbearing of 20 kg/2cm2
– Non-toxic, non-inflammatory, non-genotoxic

Project ORT102 is focused on developing an optimized, recombinant immunotoxin for treatment of multiple myeloma (MM). Founded by experienced drug developers with an exclusive worldwide Commercial license from the NIH, BEORO pursues a virtual biotech business model for its lead asset BeT101. In-vitro BeT101 selectively kills primary myeloma cells with picomolar potency and in-vivo it has achieved complete cures in two MM xenograft models. BEORO seeks series A investment of €13 mio to develop GMP and analytics processes, perform GLP Tox assessment, and demonstrate clinical proof of concept in a phase 1 study within the next 3 years.

The drug developed by the project is the first oral therapy to repair fractures and keep bones strong. Through preliminary animal experiments and observational studies in more than 1,000 patients outside the United States, the company has proven the efficacy of its drugs in treating fractures, restoring bone tissue, and curing other bone diseases.